These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 33400149)
1. Somatostatin receptor-positive breast lesions on Has Simsek D; Isik EG; Engin MN; Kuyumcu S; Mudun A; Sanli Y Ann Nucl Med; 2021 Feb; 35(2):270-277. PubMed ID: 33400149 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of somatostatin receptor expressing tumor volume calculated from Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging with [ Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275 [TBL] [Abstract][Full Text] [Related]
6. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
14. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
16. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220 [TBL] [Abstract][Full Text] [Related]
17. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461 [TBL] [Abstract][Full Text] [Related]
18. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma. Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126 [TBL] [Abstract][Full Text] [Related]
19. Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on Gao J; Zhou J; Liu C; Pan Y; Lin X; Zhang Y J Cancer Res Clin Oncol; 2024 May; 150(5):272. PubMed ID: 38795250 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience. Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]